Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06961084
PHASE2

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

Sponsor: Thomas Hope

View on ClinicalTrials.gov

Summary

Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.

Official title: Comparison of I-124 PET/CT to I-123 Whole Body Imaging for the Diagnosis of Thyroid

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

62

Start Date

2025-07-14

Completion Date

2026-03-31

Last Updated

2026-01-07

Healthy Volunteers

No

Conditions

Interventions

DRUG

Iodine-124

Given Orally

PROCEDURE

Positron Emission Tomography (PET)/Computerized tomography (CT)

Combination of PET and CT imaging

Locations (1)

University of California, San Francisco

San Francisco, California, United States